PeriRx officially launches SaliMark OSCC Test for oral squamous cell carcinoma

PeriRx LLC, a developer of noninvasive, oral diagnostic technology, has officially launched SaliMark OSCC, a molecular DNA test for the early detection of oral squamous cell carcinoma. The salivary test is now available from the online ordering systems of Henry Schein Dental, Patterson Dental, and Benco Dental.

Salimarkmsh

PeriRx LLC, a developer of noninvasive, oral diagnostic technology, has officially launched SaliMark OSCC, a molecular DNA test for the early detection of oral squamous cell carcinoma. The salivary test is now available from the online ordering systems of Henry Schein Dental, Patterson Dental, and Benco Dental.

Salimarkmsh“We’re very excited to bring this accurate, easy-to-use, and noninvasive oral cancer screening tool to market,” said Stephen M. Swanick, CEO and founder of PeriRx, LLC. “The fact that these three leading dental suppliers all agreed to distribute SaliMark OSCC is a not only a testament to its efficacy but also their recognition of the test’s strong potential to lower the mortality rate of what the National Institute of Health says is the world’s sixth leading cause of cancer, which kills one American every hour of every day.”

ADDITIONAL READING | Human papillomavirus and oral cancer

Development of the noninvasive test was based on NIH-funded research, with initial discovery and prevalidation work conducted by Dr. David Wong of the University of California at Los Angeles. In addition, more than 10 years of research at National Institute of Dental and Craniofacial Research and National Institute of Health supports SaliMark OSCC as a scientifically validated molecular DNA biomarker test for oral squamous cell carcinoma.

ADDITIONAL READING |Increasing dental case acceptance through the use of salivary diagnostics

The test is indicated for use when a visual oral examination (via naked eye or fluorescent device) detects a suspicious lesion or oral mucosal abnormality. SaliMark OSCC’s highly-accurate risk assessment capabilities can help the clinician make a more informed and confident decision on whether to refer the patient to a specialist for a biopsy.

“Although biopsies are the gold standard for determining pathology, they are invasive procedures that come back negative 90% of the time,” explained Swanick. “SaliMark will greatly improve the efficiency and accuracy of any oral cancer exam protocol.”

For more information about PeriRx, LLC or its SaliMark OSCC salivary test for oral squamous cell carcinoma, including scientific data, presentations, videos, peer-reviewed dental journal articles, and product literature, visit www.PeriRx.com, call (610) 544-3500, or send an email toinfo@PeriRx.com.

SaliMark OSCC is not yet approved for sale in the state of New York. Regulatory approval process is currently in progress. However, New York dentists who preregister their practices online will be kept on file and notified immediately when SaliMark is approved for sale and use in their state.

Based in Broomall, Pennsylvania, PeriRx, LLC, was founded in 2008. The PeriRx executive team consists of CEO and founder Swanick; Dr. Neil Gottehrer, a practicing dentist; and Dr. Jack Martin, a cardiologist.

PeriRx, LLC, obtained its patented and patent-pending technologies from inventor Dr. David Wong’s firm RNAmeTRIX and the Regents of the University of California at Los Angeles. PeriRx and RNAmeTrix have ongoing agreements that ensure the continuing research and development necessary to advance product development from clinical trial, through regulatory approval, and into commercialization.

More in Best Practice